Figure 1

Response to sunitinib: FDG-PET and CT scan evaluation. (A) Baseline FDG PET/CT study: sagittal fused PET/CT image showing abnormal FDG uptakes in the left foot tumor (circle; SUVmax 12.0) and in soft tissue metastatic nodules in the ankle and leg (arrows); (B) After 8 weeks of treatment with SM 37.5 mg/day, PET/CT re-evaluation shows a complete metabolic response of the foot lesion (circle; SUVmax 2.5; ΔSUV −79%) and the disappearance of the soft tissue nodules. (C) CT scan (venous phase after contrast medium) shows a complete response to a right inguinal lymph node after 3 months of treatment with sunitinib (green arrow), compared to baseline (red arrow).